Dr. Lappalainen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3900 Woodland Ave
Vamirecc
Philadelphia, PA 19104Phone+1 203-676-1599
Education & Training
University of Pennsylvania Health SystemFellowship, Addiction Psychiatry, 2014 - 2015
Yale-New Haven Medical CenterResidency, Psychiatry, 2001
OtherClass of 1992
Certifications & Licensure
DE State Medical License 2015 - 2027
PA State Medical License 2013 - 2026
CT State Medical License 1999 - 2015
American Board of Psychiatry and Neurology Psychiatry- American Board of Psychiatry and Neurology Addiction Psychiatry
Clinical Trials
- A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression Start of enrollment: 2017 Dec 28
Publications & Presentations
PubMed
- Effect of fasedienol (PH94B) pherine nasal spray and steroidal hormones on electrogram responses and autonomic nervous system activity in healthy adult volunteers.Louis Monti, Rita Hanover, Ester Salmán, Ross A Baker, Jaakko Lappalainen
Human Psychopharmacology. 2024-03-01 - 22 citationsGABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humansAurelija Jucaite, Zsolt Cselényi, Jaakko Lappalainen, Dennis J. McCarthy, Chi-Ming Lee
Psychopharmacology. 2017-02-01 - 17 citationsA 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipationLynn R. Webster, Raj Tummala, Ulysses Diva, Jaakko Lappalainen
Journal of Opioid Management. 2016-11-01
Press Mentions
Marinus Announces Positive Preliminary Data from Children with CDKL5 Genetic DisorderJanuary 23rd, 2017
Why This Seizure Drug Matters so Much for Marinus PharmaJanuary 23rd, 2017
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific ConferencesNovember 8th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
